Kronos Bio, Inc.

NasdaqGS:KRON 株式レポート

時価総額:US$52.8m

Kronos Bio 過去の業績

過去 基準チェック /06

Kronos Bioの収益は年間平均-15%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間19.1% 90.2%割合で 増加しています。

主要情報

-15.0%

収益成長率

25.2%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率90.2%
株主資本利益率-77.0%
ネット・マージン-867.7%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Jun 20
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Jun 11
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio: Still Promising But Riskier Following ASCO Update

Jun 05

Kronos Bio: Underestimated Drug Discovery Platform

May 06

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Jan 19
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

Aug 21
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Feb 22
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Nov 01
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib

Aug 16

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Jul 07
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

Feb 01
We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Mar 03
How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

Jan 09
Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

Kronos Bio  EPS misses by $4.10

Nov 18

収支内訳

Kronos Bio の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:KRON 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 2410-863256
30 Jun 248-1033669
31 Mar 248-1164076
31 Dec 236-1134281
30 Sep 234-1194386
30 Jun 233-1204484
31 Mar 231-1234586
31 Dec 220-1334691
30 Sep 220-16448118
30 Jun 220-16546120
31 Mar 220-16145117
31 Dec 210-15142110
30 Sep 210-1223971
30 Jun 210-1283563
31 Mar 210-1082750
31 Dec 200-881939
30 Sep 200-611132
30 Jun 200-25620
31 Mar 200-20417
31 Dec 190-16313

質の高い収益: KRONは現在利益が出ていません。

利益率の向上: KRONは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: KRONは利益が出ておらず、過去 5 年間で損失は年間15%の割合で増加しています。

成長の加速: KRONの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: KRONは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。


株主資本利益率

高いROE: KRONは現在利益が出ていないため、自己資本利益率 ( -77.02% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘